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CARDIAC AND PULMONARY 
REPLACEMENT 
CARDIAC GENE TRANSFER 
BY INTRACORONARY 
INFUSION OF ADENOVIRUS 
VECTOR-MEDIATED 
REPORTER GENE IN 
THE TRANSPLANTED 
MOUSE HEART 
This study introduces a model for intracoronary gene transfer in murine 
cardiac isografts using adenovirus vectors. This approach may offer an 
opportunity to modulate alloreactivity after cardiac transplantation. Donor 
hearts were infected via the coronary arteries with a volume of 109 plaque- 
forming units per milliliter of a recombinant adenovirus containing the 
B-galactosidase-encoding gene (Ad.CMVLacZ). In a control group, 200/~l of 
normal saline solution was infused. The grafts were stored in 4 ° C cold saline 
solution for 15 minutes, then transplanted heterotopically into syngeneic hosts 
(B10.BR). The grafts were harvested at 3, 7, 15, or 30 days (n = 5 for each 
group) after transplantation, and lB-galaetosidase activity was assessed by 
histochemical staining (X-gal). All grafts were functioning when harvested. 
X-gal staining pattern was nonuniform with positive staining appearing in 
epicardial, myocardial, and endocardial cells, as weil as in the vessel walls. The 
cells permissive to infection consisted predominantly ofmyocardial cells. The 
mean total numbers of iß-gal-positive staining cells per slice were 68.7 - 27.3 
in the 3-day group, 330.4 +- 53.8 in the 7-day group, 151.3 + 48.0 in the 15-day 
group, and 39.9 --- 10.8 in the 30-day group, thus peaking in the 7-day group 
(p < 0.05). Control isografts (n = 5), retrieved at day 30, revealed no staining 
activity. In conclusion, our model demonstrates that intracoronary gene 
transfer to the transplanted murine cardiac grafts is feasible at the time of 
harvest. Adenovirus-mediated gene transfer produces widespread gene expres- 
sion which, though perhaps transient, does not adversely affect myocardial 
structure or function. This technology may allow modification of graft immu- 
nogenicity in the future through the production of therapeutic proteins 
sutticient to modulate local immune responses. (J THORAC CARDIOVASC SURG 
1996;111:246-52) 
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T he development of methods to transfer genes into the heart has opened a new era in cardio- 
vascular therapeutics. Through the localized expres- 
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sion of gene products, gene transfer approaches can 
provide insight into cardiac cell biology and may 
allow treatment of cardiac diseases uch as trans- 
plantation coronary artery disease or graft rejection. 
Several methods of transfecting enes have been 
studied. In vivo, direct myocardial gene transfer 
through a needle has been investigated in the rat, I-5 
rabbit, microswine, 6 and dog. 7 However, the limited 
spatial extent of transfection has restricted the clin- 
ical applicability of this technique to human heart 
diseases. 4 By way of overcoming these limitations, 
the transvascular pproach as been investigated as 
a potential target for gene therapy because of the 
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large surface area and widespread istribution. Two 
types of approaches have been used to transfer 
genes into endothelial cells in vivo. First, genes have 
initially been transferred into endothelial cells in 
vitro, followed by reintroduction of the transfected 
cells into the vessel wall J  -1° Second, the genes have 
been transferred in vivo directly into the vessel 
wall. 11-13 However, the fact that endothelial cells 
replicate slowly in the resting state may become a 
limiting factor for the use of vectors that depend on 
cell proliferation to express the exogenous genes. ~4 
A unique feature of adenovirus vectors is that they 
appear to be efficient in transferring foreign genes 
even into slowly replicating endothelial cells. 1° 
The application of gene transfer techniques to the 
coronary vessels of cardiac allografts may offer 
insight into the alteration of alloantigen expression 
in the grafts and ultimately may allow the treatment 
of transplantation coronary artery disease or al- 
lograft rejection. Early detectable expression of 
genes after intracoronary infusion of a reporter gene 
at the time of harvest has been reportedJ  3
In the present study, we evaluated the potential 
utility of adenovirus-mediated cardiac gene transfer 
by direct infiJsion of  a reporter gene into the coro- 
nary arteries of the transplanted mouse heart. 
Material  and methods 
Gene and adenovirus vector. The replication-defective 
recombinant adenovirus (Ad.CMVLacZ) encoding the 
Escherichia coli LacZ gene, capable of producing the 
enzyme /3-galactosidase, was used as a reporter gene. 
The gene was modified by the addition of sequences 
encoding for a nuclear translocation signal and was placed 
under a control of the cytomegalovirus long terminal 
repeat, A volume of 200 txl of 109 PFU/ml* of viral 
particles was infused into the donor coronary arteries. 
Animals. Fifty adult mice (7 to 10 weeks of age) of the 
B10.BR strain, weighing 17 to 22 gm, were obtained from 
Jackson Laboratories (Bar Harbor, Maine). They were 
housed under cõnventional conditions and red a standard 
diet (Rodent Laborato~ Chow, Ralston Purina Company, 
St. Louis, Mo.) and water. After completion of each 
procedure, the mice were allowed to recover with oxygen 
and local heat and transferred to their cages 24 hours after 
the operation with free access to food. 
Heterotopic heart transplantation and intracoronary 
gene transfer,, Cardiac isografls from B10.BR mice were 
transplanted into a seeond set of B10.BR mice by means 
of standard microsurgical techniques. After adequate 
anesthesia with 4% chloral hydrate (0.1 tal/20 gm of body 
weight, intraperitoneal injection) and methoxyflurane (in- 
halation), a sternal lid was lifted upward and fixated. Both 
the right and the left superior venae cavae were ligated. 
*PFU/ml = Plaque-forming unit per milliliter. 
The donor heart was arrested by infusion of 0.5 ml of cold 
heparinized saline solution into the inferior vena cava 
(100 U heparin per milliliter saline solution). The left 
pulmonary artery was transected to vent the coronary 
sinus, and the ascending aorta was ligated just proximal to 
the origin of the innominate artery. The viral particles 
were then infused into the proximal aorta with a 27-gauge 
needle. In all cases, outflow of infused solution through 
the proximal cut end of the left pulmonary artery con- 
firmed adequacy of delivery. The aorta, main pulmonary 
artery, and the three systemic veins were then transected 
distal to ligatures, followed by the en bloc ligature and 
transection of the pulmonary veins. The donor heart was 
preserved in 4 ° C normal saline solution during recipient 
preparation. 
Through a midline abdominal incision, the recipient's 
infrarenal abdominal aorta and inferior vena cava were 
isolated and ligated both proximally and distally with 5-0 
silk. After a longitudinal aortic incision, an end-to-side 
anastomosis between the donor ascending aorta and the 
recipient abdominal aorta was performed, followed by an 
end-to-side anastomosis between the donor pulmonary 
artery and recipient inferior vena cava. Both anastomoses 
were sutured with 10-0 nylon. The recipient's proximal 
aortic ligature was released first so that the graft would be 
initially reperfused with blood from the proximal aorta. 
Expression of 13-galactosidase. Histochemical staining 
was done so that/3-galactosidase ctivity could be exam- 
ined. Cross sections, 3 to 4 mm in height, were taken from 
the graft at midventricular level and snap-frozen i  liquid 
nitrogen. Then 10 /xm thick slices were cut at 200 /xm 
intervals, followed by fLxation with 1.25% glutaraldehyde. 
After being washed three times at room temperature with 
phosphate-buffered solution, the slices were stained for 
/3-galactosidase with X-gal (5-bromo-4-chloro-indolyl/3-D- 
galactopyronoside) for 4 to 6 hours, as previously de- 
scribed, x» Six slices were examined for each mouse. For 
quantitative analysis of gene expression, the total number 
of cells positively staining for 13-galactosidase was counted 
per slice under magnification (x40), and a mean value 
was calculated for six slices. Then, overall mean values 
were determined for each group (i.e., 3-, 7-, 15-, 30-day, 
and control groups). With the aforementioned regimen, 
LacZ expression was represented by a nuclear-dominant 
blue color. 
Animal care. All animals received humane care in 
compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of Labora- 
tory Animals" prepared by the Institute of Laborätory 
Animal Resonrces and published by the National Institutes 
of Health (NIH publication No. 85-23, revised 1985). 
Statistieal analysis. Numbers are expressed as mean _+ 
standard eviation of the number observed. The differ- 
ence of the amount of gene expression was evaluated with 
analysis of variance. The level of significance was accepted 
as p < 0.05. 
Result 
Survival. All donor hearts resumed sinus rhythm 
after several minutes of reperfusion. Total ischemic 
Fig. lA. Successful gene transfer to the cardiac graft was demonstrated with X-gal staining (expressed as 
blue spots) in myocardial cells of coronary vessels. 
Fig. 1B. Successful gene transfer to the cardiac graft was demonstrated with X-gal staining (expressed as 
blue spots) in endothelial cells of coronary vessels. 
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Fig. 1C. Successful gene transfer to the cardiac graft w s demonstrated with X-gal staining (expressed a  
blue spots) in smooth muscle cells of coronary vessels. 
time of the donor hearts ranged between 45 and 65 
minutes. Nonsurvival rate, defined as survival for 
less than 24 hours after transplantation, was less 
than 10%. All animals urviving cardiac transplan- 
tation lived until they were sacrificed. All recipients 
had normal contractility of the transplanted heart 
when sacrificed. Aside from the /3-galactosidase 
staining, the« histologic appearances of both the 
experimental nd control groups were normal. 
Infection pattern and time eourse of expression. 
Successful gene transfer and expression of 13-galac- 
tosidase was documented in all animals killed at 3 
days. X-gal staining patterns revealed anonuniform 
distribution, with blue-¢olored positively staining 
cells appearing in epicardial, myocardial, and endo- 
cardial cells, as well as in vascular walls (Figs. lA, 
1B, and IC). The cells permissive to infection con- 
sisted predominantly of myocardial cells, and other 
myocardial structures w re relatively well preserved 
(Fig. lA), The mean total numbers of cells staining 
positively for 13-galactoside p r slice were 68.7 _+ 
27.3 in the 3-day group, 330.4 ± 53.8 in the 7-day 
group, 151.3 _+ 48.0 in the 15-day group, and 39.9 +_ 
10.8 in the 30-day group, peaking in the 7-day group 
(p < 0.05). Control isografts (n = 5), retrieved at 
day 30, revealed no staining activity (Fig. 2). 
Discussion 
The present study proposes a model for adenovi- 
rus-mediated gene transfer to transplanted ¢ardia¢ 
grafts and confirms the findings of recent studies on 
direct gene transfer into murine coronary arteries. ~3 
We observed expression of the LacZ gene, which is 
capable of producing the 13-galactosidase enzyme, in 
the epicardial, myo¢ardial, and endo¢ardial cells, as 
weil as in the coronary vascular walls, up to 30 days 
after transplantation, which demonstrates that this
technique is a feasible means of transferring genes 
at the time of harvest. 
Since Wolff and associates ~5demonstrated that 
murine skeletal muscle can take up and express 
genes that have been injected directly into the 
muscle, both skeletal and cardiac myocytes have 
been found to be efficient targets for gene transfer, ló
Several investigators have shown that expression of 
reporter genes injected into the skeletal or ¢ardiac 
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Fig. 2. Life span of transfected gene expression within 
the graft was analyzed by comparing the total number of 
cells staining positively for /~-galactosidase p r slice 
between the groups. Gene expression was detected in 
the 3-day group, peaking at 7 days, and gradually 
declined thereafter. 
muscle was higher than for other injected tissues, 
including the brain, liver, spleen, uterus, stomach, 
lung, or kidney. 1' 2, 15 Although the reason for such 
apparently superior esults remains unclear, it has 
been hypothesized that structural differences, in- 
cluding the presence of multinucleated cells, a sar- 
coplasmic reticulum, and a rich T-tubule system in 
skeletal and cardiac muscle, may allow better access 
of the gene to these cell populations. 1'2' 15 The 
mechanism whereby the gene injectate is taken up 
by muscuiar tissues is unknown. It has been reported 
that only cells directly adjacent to the injection site 
are transfected, suggesting uptake of deoxyribonu- 
cleic acid (DNA) through leaking cell mem- 
branes.1, 6 This finding, in addition to other experi- 
mental findings, raises questions about the clinical 
applicability of the direct injection method for trans- 
fection of human myocardium. These findings in- 
clude the small number of myocytes that can be 
transfected in vivo (as few as 60 to 100 cells per 
injection), complete transfection only at the cells 
bordering the needle tract, and the occurrence of 
inflammation, myocardial necrosis, and scar forma- 
tion along the needle tract. ~' 2 
Unlike direct myocardial injection, transfection 
via the walls of the coronary vasculature can be a 
useful means of gene transfer because of the poten- 
tially large absorptive area and widespread istribu- 
tion. In vitro endothelial or vascular smooth muscle 
cells expressing a recombinant gene can be im- 
planted on porcine endothelium-denuded vessel 
walls in vivo 8' 10 or on prosthetic interposition grafts 
of canine carotid arteries. 9 However, this technique 
requires prolonged occlusion of the target vessels to 
faeilitate adenovirus attachment to the vascular 
wall,8, 10 and it has a limited human application 
because of the practical difficulty of obtaining endo- 
thelial cells in advance. 11 Direct gene transfer into 
the unmodified vessels may overcome these prob- 
lems. Previous reports have proved the feasibility of 
direct in vivo gene transfer into blood vessels. 1113' 17 
This study demonstrated that the recombinant ade- 
novirus vector is able to transfer genes not only into 
the myocardial cells but also into the coronary 
arterial walls, the sites of local immune interactions 
after cardiac transplantation. 
Recently, the adenovirus vector has been shown 
to be efficient in transferring exogenous genes into a 
variety of cells both in vitro and in vivo. 18-22 This 
vector has a number of advantages over other viral 
vectors. It is capable of infecting either nondividing 
or slowly proliferating cells, for example, vascular 
endothelial cells. 5' 23 Lemarchand and coworkers 1° 
have observed that replication-deficient adenovirus 
vector can mediate detectable gene expression in 
normal endothelial cells. The present study demon- 
strates that coronary vascular cells with/3-galactosi- 
dase expression remain relatively intact microscop- 
ically. Other advantages of adenovirus vectors 
include the potential of generating viral stocks in 
excess of 1 × 1011 PFU/ml, an ability to accept 
heterologous genes up to 7.5 kb in length, no 
reported associations with human malignancies, and 
a history of safe administration i  human vaccines. 24 
Moreover, gene expression after adenovirus-medi- 
ated transfection i  vivo could persist longer than 
other viruses. The mechanism underlying this phe- 
nomenon is unclear, but persistence of a moderate 
degree of viral replication may be responsible. A
potential downside of this continued replication is 
that it may lead to a powerful host immune response 
to the infected cells. 23 A long-term model would be 
needed to examine this possible adverse ffect. 
An additional imitation regarding the general- 
ized use of viral vectors has been the length of time 
required to generate ach recombinant virus. Previ- 
ous study has shown that an 18- to 24-hour incuba- 
tion period is required to get the maximal lipofectin- 
mediated luciferase gene transfer in in vitro 
endothelial cell cultures. 11 Actually, such a long 
incubation period is not practical for in vivo gene 
transfer. In contrast, a considerable number (58%) 
of the endothelial cells expressed the /3-galactosi- 
dase when the adenovirus vector (Ad.RSV/3-gal) 
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was in contact with the endothelial cells for even as 
short a period as 15 minutes in in vitro endothelial 
cell culture. 1° In the present study, the interval 
between the harvest and the reperfusion of the 
grafts (15 minutes of preservation in 4°C saline 
solution plus 45 minutes of room temperature ex- 
posure) was the incubation period. Clinically, the 
ischemic time of allografts provides aunique oppor- 
tunity for access to the allografts and a window for 
direct gene transfer. Further studies are necessary, 
however, to demonstrate whether g ne transfer can 
occur at hypothermic temperatures u ed for cardiac 
preservation. 
The analysis of the time course of gene expression 
in our model corroborates the results obtained by 
others. Lemarchand and associates ~° observed that 
expression with adenovirus vectors peaked at 7 days 
and then declined, so that expression was no longer 
evident at 28 days in the in vivo carotid artery and 
umbilical vein of the lamb. Acsadi and coworkers 2 
demonstrated that no/3-galactosidase-positive cells 
were seen 25 days after direct myocardiai injection 
of pRSVLacZ, suggesting that injected DNA re- 
mains episomal and is lost over time because of 
rapid target cell turnover. Additionally, they found 
that luciferase activity was table for 60 days in 
cyclosporine-treated rats compared with unstable 
expression in untreated rats, 2 suggesting that an 
immune mechanism may be responsible for gene 
elimination. Nabel, Pautz, and Nabel 25 observed 
that 13-galactosidase activity was expressed for at 
least 5 months after they transfected a segment of 
the iliofemoral arteries with retrovirus in vivo, and 
all three layers of the vessels including endothelial 
and vascu!ar smooth muscle cells were infected by 
the retrovirus. Further efforts to increase the func- 
tional life span of viruses injected into infected 
organs need to be explored. 
In sumrna1% our model demonstrates that intra- 
coronary gene transfer to the transplanted murine 
cardiac grafts is feasible at harvest. Adenovirus- 
mediated gene transfer produces widespread gene 
expression which, though perhaps transient, does 
not adversely affect myocardial structure or func- 
tion. Thi s technology may allow modification of 
graft immunogenicity in the future by using gene 
sequences capable of encoding immunosuppressive 
proteins, itowever, further efforts directed at in- 
creasing the level of expression and the functional 
life span of gene sequences need to be applied for 
this technique to be useful in patients. 
REFERENCES 
1. Lin H, Parmacek MS, Morle G, Bolling S, Leiden JM. 
Expression of recombinant genes in myocardium in
vivo after direct injection of DNA. Circulation 1990; 
98:2217-21. 
2. Acsadi G, Jiao S, Jani A, et al. Direct gene transfer 
and expression into rat heart in vivo. New Biol 
1991;3:71-81. 
3. Wang J, Jiao S, Wolff JA, Knechtle SJ. Gene transfer 
and expression i rat cardiac transplants. Transplan- 
tation 1992;53:703-5. 
4. Buttrick PM, Kass A, Kitsis RN, Kaplan ML, Lein- 
wand LA. Behavior of genes directly injected into rat 
heart in vivo. Circ Res 1992;70:193-8. 
5. Guzman R J, Lemarchand P, Crystal RG, Epstein SE, 
Finkel T. Efficient gene transfer into myocardium by 
direct injection of adenovirus. Circ Res 1993;73: 
1202-7. 
6. Gal D, Weir L, Leclerc G, Pickering JG, Hogan J, 
Isner JM. Direct myocardial transfection i two ani- 
mal models: evaluation of parameters affecting ene 
expression and percutaneous gene therapy. Lab Invest 
1993;18:18-25. 
7. von Harsdorf R, Schott R J, Shen Y-T, Vatner SF, 
Mahdavi V, Nadal-Ginard B. Gene injection into 
canine myocardium as a useful model for studying 
gene expression i the heart of large mammals. Circ 
Res 1993;72:088-95. 
8. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel 
GJ. Recombinant gene expression in vivo within 
endothelial cells of the arterial wall. Science 1989;244: 
1342-4. 
9. Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow 
AD, Mulligan RC. Implantation of vascular grafts 
lined with genetically modified endothelial cells. Sci- 
ence 1989;244:1344-6. 
10. Lemarchand P, Jones M, Yamada I, Crystal RG. In 
vivo gene transfer and repression i normal uninjured 
blood vessels using replication-deficient recombinant 
adenovirus vectors. Circ Res 1993;72:1132-8. 
11. Lim CS, Chapman GD, Gammon RS, et al. Direct in 
vivo gene transfer into coronary and peripheral vas- 
culatures of the intact dog. Circulation 1991;83:2007- 
11. 
12. Chapman GD, Lim CS, Gammon RS, et al. Gene 
transfer into coronary arteries of intact animals with a 
percutaneous balloon catheter. Circ Res 1992;71:27- 
33. 
13. Ardehali A, Fyfe AI, Laks H, Drinkwater DC, Qiao 
JH, Lusis AJ. Direct gene transfer into donor hearts 
at the time of harvest. J THORAC CARDIOVASC SURG 
1995;109:716-9. 
14. Miller DG, Adam MA, Miller AD. Gene transfer by 
retrovirus vectors occurs only in cells that are actively 
replicating at the time of infection. Mol Cell Biol 
1990;10:4239-42. 
15. Wolff JA, Malone RW, Williams P, et al. Direct gene 
252 Lee et al. 
The Journal of Thoracic and 
CardJovascular Surgery 
January 1996 
transfer into mouse muscle in vivo. Science 1990;247: 
1465-8. 
16. Stratford-Perricaudet LD, Makeh I, Perricaudet M, 
Briand P. Widespread long-term gene transfer to 
mouse skeletal muscles and heart. J Clin Invest 1992; 
90:626-30. 
17. Flugelman MY, Jaklitsch MT, Newman KD, Casscells 
W, Bratthauer GL, Dichk DA. Low level in vivo gene 
transfer into arterial wall through a perforated bal- 
loon catheter. Circulation 1992;85:1110-7. 
18. Kirshenbaum LA, MacLellan WB, Majur W, French 
BA, Schneider MD. Highly etficient gene transfer into 
adult ventricular myocytes by recombinant adenovi- 
rus. J Clin Invest 1993;92:381-7. 
19. La Salle GLG, Robert JJ, Berrad S, et al. An adeno- 
vius vector for gene transfer into neurons and glia in 
the brain. Science 1993;259:988-90. 
20. Rosenfeld MA, Siegfried W, Yoshimura K, et al. 
Adenovirus-mediated transfer of a recombinant c~ 1- 
antitrypsin gene to the lung epithelium. Science 1991; 
252:431-4. 
21. Smythe WR, Kaiser LR, Hwang HC, et al. Successful 
adenovirus mediated gene transfer in an in vivo model 
of human malignant mesothelioma. Ann Thorac Surg 
1994;57:1395-401. 
22. Haddada H, Lopez M, Martinache C, Ragot T, Abina 
MA, Perricaudet M. Efficient adenovirus mediated 
gene transfer into human blood monocyte-derived 
macrophage. Biochem Biophys Res Commun 1993; 
195:1174-83. 
23. Mulligan RC. The basic science of gene therapy. 
Science 1993;260:926-32. 
24. Berkner KL. Development of adenovirus vectors for 
expression of heterogenous genes. Biotechniques 
1988;6:616-29. 
25. Nabel EG, Pautz G, Nabel GY. Gene transfer into 
vascular cells. J Am Coll Cardiol 1991;17:189B-94B. 
Discussion 
Dr. John E. Mayer (Boston, Mass.). Genetic modifica- 
tion of donor allografts by means of viral vectors offers an 
exciting potential avenue by which both acute and chronic 
rejection may be modified. 
Two questions have occurred to me. First, although 
rauch of your interest seems to have been focused on 
endothelial cells and transplant atherosclerosis, the great 
majority of infected cells were myocytes. Do you have any 
explanation for this? Does this finding imply that a 
different viral vector may be necessary or should the dose 
of the virus be greater? 
Second, can you speculate on which genes should be 
transferred into the donor hearts? I have wondered 
whether the donor cells could be induced to produce the 
same HLA antigens as the recipient. Do you have any 
other ideas concerning which genes could be transferred 
into the donor organ? 
Dr. Lee. Dr. Mayer, thank you for your comments and 
questions. First, our model was the first step study to 
evaluate the spacial and temporal expression pattern of 
adenovirus-mediated gene transfer in the transplanted 
mouse heart. It is true that the endothelial cells are 
thought o be among the useful targets to transfect genes 
to modulate local immune responses after cardiac trans- 
plantation because of their large absorptive area and 
widespread istribution. Recently, adenovirus vector has 
been shown to be an elficient ool to transfect genes even 
into nondividing or slowly dividing cells like myocardial or 
endothelial cells in both in vivo and in vitro studies. As 
you commented, our results revealed that myocardial cells 
were more efficiently transfected than the endothelial 
cells. However, the gene expressions in both myocardium 
and endothelium of the coronary vascular beds, the sites 
of local immune responses, were demonstrated in this 
study. This may justify the possible role of this approach to 
treat either transplantation coronary artery disease or 
graft rejection. The relative efficiency of transfection to 
the different cell types is to be studied further. 
Second, there is no doubt that the long-term goal of 
these experiments i to develop the methods to express 
the transferred genes and to produce biologically active 
proteins in quantities utficient to modulate local immune 
responses. Application of this technology using gene 
sequences for immunosuppressive cytokines including 
transforming growth factor-/3 (TGF-/3) and interleukin-10 
is currently underway with favorable results. Further efforts 
should be directed toward ways to increase the functional lee 
span and rate of infection of these inserted gene sequences 
for this technology to be clinically applicable. 
Dr. John H. Kennedy (Cambridge, England). Homocys- 
tine has recently been implicated as a risk factor in 
atherosclerosis, and the cytomegalovirus family of viruses 
is thought o invoke this response. Homocystine remains 
in tissue or body fluids for as long as 10 years. Ifyou have 
any frozen material, it might be interesting to see whether 
a different virus would be more useful in your particular 
model if you are interested in graft rejection and acceler- 
ated atherosclerosis. 
